

IN THE CLAIMS:

This listing of claims below will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1 to 22 (Canceled)

Claim 23. (Currently amended) A method of treating premature ejaculation, the method comprising administering to a subject in need of such treatment a dry powder composition comprising an antidepressant by pulmonary inhalation, wherein ~~the composition provides an onset of the therapeutic effect within no more than 30 minutes following pulmonary administration, and wherein the anti-depressant is clemipramine~~ at least 90% of the antidepressant has a mass median aerodynamic diameter particle size of 10µm or less.

Claim 24. (Original) A method as claimed in claim 23, wherein the method does not cause the adverse side effects normally associated with the administration of the antidepressant.

Claims 25 to 38 (Canceled)

Claim 39. (Previously presented) A method as claimed in claim 23, wherein the composition comprises two or more antidepressants.

Claim 40. (Previously presented) A method as claimed in claim 23, wherein the composition comprises a further therapeutic agent, which is not an antidepressant.

Claim 41. (Previously presented) A method as claimed in claim 40, wherein the further

therapeutic agent is also effective in treating PE.

Claim 42. (Previously presented) A method as claimed in claim 40, wherein the further therapeutic agent is a benzodiazepine.

Claim 43 (Previously presented) A method as claimed in claim 23, wherein the composition provides a dose of antidepressant of less than 25mg.

Claim 44 to 45 (Canceled)

Claim 46. (Previously presented) A method as claimed in claim 23, wherein the composition comprises particles of antidepressant having a mass median aerodynamic diameter of about 10 μ m or less.

Claim 47. (Previously presented) A method as claimed in claim 46, wherein the mass median aerodynamic diameter is about 5 μ m or less.

Claim 48. (cancelled)

Claim 49. (Previously presented) A method as claimed in claim 48, wherein at least 90% of the antidepressant has a particle size of about 5 μ m or less.

Claim 50. (Previously presented) A method as claimed in claim 23, wherein the composition further comprises an additive material.

Claim 51. (Previously presented) A method as claimed in claim 50, wherein the additive material is provided in an amount from about 0.15% to about 5% of the medicament, by

weight.

Claim 52. (Previously presented) A method as claimed in claim 50, wherein the additive material is selected from the group consisting of leucine, magnesium stearate, lecithin, and sodium stearyl fumarate.

Claim 53. (Previously presented) A method as claimed in claim 23, wherein the composition further comprises an excipient material.

Claim 54. (Previously presented) A method as claimed in claim 53, wherein the excipient material is in the form of carrier particles having an average particle size of about 40 to about 70 μm .

Claim 55 (Previously presented) A method as claimed in claim 23, wherein the composition comprises a solution pMDI formulation including a propellant, a solvent and water.

Claim 56 (Previously presented) A method as claimed in claim 23, wherein the composition is a suspension pMDI formulation including a propellant.

Claim 57 (Previously presented) A method as claimed in claim 56, wherein the propellant is selected from the group consisting of: HFA134a, HFA227 and a combination thereof.

Claim 58. (Canceled)

Claim 59. (Previously presented) A method as claimed in claim 23, wherein the composition provides a dose of antidepressant of less than 15mg.

Claim 60. (Previously presented) A method as claimed in claim 23, wherein the composition

provides a dose of antidepressant of less than 5mg.

Claim 61. (Previously presented) A method as claimed in claim 23, wherein the composition provides an onset of the therapeutic effect within no more than 20 minutes following pulmonary administration.

Claim 62. (Previously presented) A method as claimed in claim 23, wherein the composition provides an onset of the therapeutic effect within no more than 10 minutes following pulmonary administration.

Claim 63. (Previously presented) A method as claimed in claim 23, wherein the composition provides an onset of the therapeutic effect within no more than 5 minutes following pulmonary administration.

Claim 64. (Previously presented) A method as claimed in claim 23, wherein the composition provides an onset of the therapeutic effect within no more than 1 minute following pulmonary administration.

Claim 65. (new) A method as claimed in claim 23, wherein the composition provides an onset of the therapeutic effect within no more than 30 minutes following pulmonary administration.